Gloria Melanie 4
4 · Immunovant, Inc. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Immunovant (IMVT) COO Gloria Melanie Sells Shares
What Happened
- Gloria Melanie, Chief Operating Officer of Immunovant, sold 3,238 shares on Feb 25, 2026 in three open-market disposals to cover tax withholding tied to vested RSUs. Reported amounts: 1,437 shares @ $26.98 ($38,770), 859 shares @ $28.16 ($24,189), and 942 shares @ $28.90 ($27,224), for total proceeds of about $90,183.
- This was a sale to satisfy tax obligations following the vesting/settlement of RSUs and was mandated by the issuer’s “sell to cover” election — a routine, non‑discretionary transaction rather than a voluntary decision to liquidate holdings.
Key Details
- Transaction date: 2026-02-25; Form 4 filed 2026-02-27 (timely filing).
- Reported prices are weighted averages; the underlying trades occurred within ranges: $26.66–$27.60, $27.67–$28.61, and $28.70–$29.13 (per footnotes).
- Total shares sold: 3,238; total proceeds reported ≈ $90,183.
- Sale related to RSUs originally granted 11/18/2024; 6,872 RSUs vested on 2/18/2026 (footnote F1). The sale was to cover tax withholding (footnote F1); F2–F4 explain price ranges/weighted averages.
- Shares owned after the transaction are not specified in the provided excerpt.
Context
- This was a tax-withholding (sell-to-cover) sale tied to RSU vesting, which is common and generally not read as a personal bearish signal. The filing indicates multiple executions aggregated into weighted-average prices; the Reporting Person can provide detailed per-trade prices on request.
Insider Transaction Report
Form 4
Immunovant, Inc.IMVT
Gloria Melanie
Chief Operating Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-02-25$26.98/sh−1,437$38,770→ 172,074 total - Sale
Common Stock
[F1][F3]2026-02-25$28.16/sh−859$24,189→ 171,215 total - Sale
Common Stock
[F1][F4]2026-02-25$28.90/sh−942$27,224→ 170,273 total
Footnotes (4)
- [F1]On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on February 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.66 - $27.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 - $28.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.70 - $29.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Signature
/s/ Tiago Girao, attorney-in-fact for Melanie Gloria|2026-02-27